Compare Gilead Sciences, Inc. (GILD) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SOLAI Limited — how do they compare? Gilead Sciences, Inc. trades at $133.72 (market cap $163.51B), while SOLAI Limited trades at $2.91 (market cap $14.13M). The key difference: Gilead Sciences, Inc. is far larger — about 11571.8× SOLAI Limited's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| GILD | SLAI | |
|---|---|---|
Market Cap | $163.51B | $14.13M |
Sector | Health | Technology |
52-Week High | $155.80 | $30.66 |
52-Week Low | $108.22 | $2.74 |
Enterprise Value | $178.05B | $13.77M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
SLAI trades at $3.10, down 1.27% today, with a bearish technical signal from moving averages. The company reported a net loss of $33.88 million in 2025, with negative profit margins and ROE of -114.71%. Recent news includes a reverse stock split and a going-private proposal, while the sole analyst coverage is a Hold rating.
The outlook remains challenged by persistent losses and NYSE listing concerns. Investment opportunity hinges on successful execution of AI product launches and potential privatization, but risks include weak fundamentals and high financial distress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
